Obstet Gynecol. 2023 Jun 1;141(6):1262-1288. doi: 10.1097/AOG.0000000000005202.
To assess the evidence regarding safety and efficacy of psychiatric medications to treat mental health conditions during pregnancy and lactation. The conditions reviewed include depression, anxiety and anxiety-related disorders, bipolar disorder, and acute psychosis. For information on screening and diagnosis, refer to American College of Obstetricians and Gynecologists (ACOG) Clinical Practice Guideline Number 4, "Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum" (1).
Pregnant or postpartum individuals with mental health conditions with onset that may have predated the perinatal period or may have occurred for the first time in pregnancy or the first year postpartum or may have been exacerbated in that time.
This guideline was developed using an a priori protocol in conjunction with a writing team consisting of one specialist in obstetrics and gynecology and one maternal-fetal medicine subspecialist appointed by the ACOG Committee on Clinical Practice Guidelines-Obstetrics and two external subject matter experts. ACOG medical librarians completed a comprehensive literature search for primary literature within Cochrane Library, Cochrane Collaboration Registry of Controlled Trials, EMBASE, PubMed, and MEDLINE. Studies that moved forward to the full-text screening stage were assessed by two authors from the writing team based on standardized inclusion and exclusion criteria. Included studies underwent quality assessment, and a modified GRADE (Grading of Recommendations Assessment, Development and Evaluation) evidence-to-decision framework was applied to interpret and translate the evidence into recommendation statements.
This Clinical Practice Guideline includes recommendations on treatment and management of perinatal mental health conditions including depression, anxiety, bipolar disorders, and acute postpartum psychosis, with a focus on psychopharmacotherapy. Recommendations are classified by strength and evidence quality. Ungraded Good Practice Points are included to provide guidance when a formal recommendation could not be made because of inadequate or nonexistent evidence.
评估精神科药物在治疗围产期精神健康状况方面的安全性和有效性的证据。所审查的疾病包括抑郁症、焦虑症和相关焦虑障碍、双相情感障碍以及急性精神病。如需了解筛查和诊断信息,请参考美国妇产科医师学会(ACOG)临床实践指南第 4 号“围产期精神健康状况的筛查和诊断”(1)。
患有精神健康疾病的孕妇或产后个体,其疾病发作可能早于围产期,也可能首次出现在妊娠或产后第一年,或在此期间加重。
本指南采用预先制定的方案,并由 ACOG 临床实践指南-妇产科委员会任命的一名妇产科专家和一名母胎医学专家以及两名外部专题专家组成的写作团队共同制定。ACOG 医学图书馆员在 Cochrane Library、Cochrane 协作试验注册库、EMBASE、PubMed 和 MEDLINE 中完成了针对主要文献的全面文献检索。进入全文筛选阶段的研究由写作团队的两名作者根据标准化的纳入和排除标准进行评估。纳入的研究进行了质量评估,并应用改良 GRADE(推荐评估、制定与评估分级)证据决策框架对证据进行解释并将其转化为推荐声明。
本临床实践指南包括针对围产期精神健康状况(包括抑郁症、焦虑症、双相情感障碍和急性产后精神病)的治疗和管理建议,重点是精神药理学治疗。建议按强度和证据质量分类。对于因证据不足或不存在而无法提出正式建议的情况,纳入了未经分级的良好实践要点,以提供指导。